Westlake Epoxy Unveils EpoVIVE™ Portfolio at ECS 2025: A New Era of Sustainable Solutions
24.3.2025 21:52:00 CET | Business Wire | Press release
Westlake Corporation (NYSE: WLK) announced today that Westlake Epoxy plans to launch several new products at the European Coatings Show (ECS) 2025, March 25 to 27, 2025, in Germany. Westlake Epoxy will be showcasing at booth # 5-349 its latest innovations designed to enhance robustness, safety, and performance.
At Westlake, we challenge ourselves to do more, to go further in our quest for improved sustainability. As such we strive to develop new technologies that help support customer sustainability initiatives. We are proud to present at ECS our newly introduced EpoVIVE™ portfolio of products that provide sustainability advantages as compared to traditional Westlake formulas in one or more of the following categories:
- Lower Carbon Footprint: Utilize ISCC PLUS mass-balanced bio circular or circular raw materials to reduce carbon emissions.
- Energy Efficiency: Combine renewable energy with energy-efficient practices to reduce the carbon footprint.
- Safer Materials: Use of safer materials that are free from SVHC (substances of very high concern) and CMR (carcinogenic, mutagenic and reprotoxic), improving safe handling.
- Emission Reductions: Achieve lower VOC (volatile organic compounds) waterborne epoxy resin dispersions, contributing to the reduction of VOC emissions during customer applications.
- More Circular Solutions: Support improved circularity with innovative formulations and recycling processes that allow for enhanced ability to reuse, recycle, or repurpose products in the EpoVIVE™ portfolio.
Designed to meet the increasing demand for low-emission, and SVHC-free alternatives that use bio-circular or circular materials, these cutting-edge products offer enhanced durability, corrosion protection, and ease of use while improving our environmental footprint through operational innovations and product offerings with reduced environmental impacts.
The EpoVIVE™ range introduces NEW EPIKOTE™ Resins 901 and 902, providing CMR-free alternatives to conventional C12-C14 diluted resins for high-performance flooring. The portfolio also features the AQUAREOUS™ epoxy systems enabling lower volatile organic compound (VOC), solvent-free coatings for concrete and metal, while SVHC-free AZURES™ products deliver CMR free labelled, high-performance solutions for coatings, civil engineering, and adhesives.
In addition to the EpoVIVE™ portfolio, Westlake Epoxy will introduce the ENABLING Curing Agent EPIKURE™ 6874-WZ-50, which simplifies waterborne formulations and enhances corrosion protection for smooth steel.
"Our commitment to improved sustainability drives us to continuously innovate and deliver solutions that help our customers meet their environmental and performance goals. The launch of the EpoVIVE™ portfolio and related product developments reflect Westlake Epoxy's dedication to reducing the environmental impact of our products while maintaining our high standards of quality and performance," said Karl-Martin Schellerer, Westlake Senior Vice President — Performance and Essential Materials, Europe and Asia.
To learn more about EpoVIVE™ products and Westlake Epoxy’s new innovations for the coatings industry, we invite you to participate in the presentations “New Low labelled Resin Blends for Epoxy Flooring Applications” presented by Patrick Deudon, on Tuesday, March 25th at 14:30 – 14:50, booth # 3-742, Hall 3, and “Novel Waterborne Epoxy Systems: Boosting your Coating Performance”, presented by Dominique Vandenberghe, on Wednesday, March 26th at 13:50 – 14:10, booth # 5-243, Hall 5.
Westlake Epoxy aspires to continuously improve its Environmental, Sustainable and Governance journey. Westlake Epoxy is committed to reducing its carbon footprint through purposefully sourcing more sustainable raw materials, and refining and improving manufacturing processes. Together, we are enhancing your life every day!
About Westlake
Westlake Corporation (NYSE: WLK) is a global manufacturer and supplier of materials and innovative products that enhance life every day. Headquartered in Houston, with operations in Asia, Europe, and North America, we provide the building blocks for vital solutions — from housing and construction, to packaging and healthcare, to automotive and consumer. For more information, visit the company's web site at www.westlake.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250324929717/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom